COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
COMPASS Pathways plcNASDAQ: CMPS
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables grows, but more slowly than its trailing trend
Q1 FY2026 accounts payables of $4.18M (cash outflow) rose 5.6% year over year, behind the +305.3% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -6.6% a year.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +5.6% toward the trailing-twelve-month pace of +305.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.03M USD
- Year-over-year change
- -69.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.03M | -69.1% |
| FY2024 | 2024-12-31 | 6.59M | +662.7% |
| FY2023 | 2023-12-31 | 864K | -65.4% |
| FY2022 | 2022-12-31 | 2.5M | +1631.9% |
| FY2021 | 2021-12-31 | (163K) | — |
Accounts Payables vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 accounts payables of $1.81M is the 7th largest of the 11 companies compared; the peer median is $306.68K.
- Its year-over-year change of +305.3% is the 3rd highest of 8, against a peer median of +7.9%.
- Over three fiscal years its annual growth of -6.6% compares with a peer median of +26.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $24.47M | +11282.3% | — | 2.1% | |
| LTM Sep 2026 | $15.8M | -200.0% | +45.9% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $5.43M | — | — | — |
| LTM Jun 2026 | $4.66M | -133.1% | — | 0.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.34M | +345.5% | — | 21.7% |
| LTM Jun 2026 | $3.38M | +7.9% | — | 93.6% | |
| LTM Mar 2026 | $1.81M | +305.3% | -6.6% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $1.08M | -81.9% | — | — |
| LTM Jun 2026 | $423.37K | — | +6.2% | — | |
| LTM Mar 2026 | $190K | +249.6% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CMPS) | $306.68K | +7.9% | +26.1% | 11.9% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| Deferred Income Tax | 22K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.64M | 13.12M | 17.28M | 19.52M | 13.59M |
| Change in Working Capital | (6.64M) | (30.67M) | 3.48M | 11.72M | (14.28M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (163K) | 2.5M | 864K | 6.59M | 2.03M |
| Other Working Capital | (6.47M) | (33.16M) | 2.62M | 5.13M | (16.32M) |
| Other Non-Cash Items | 1.8M | 3.27M | 86K | 4.46M | 131.1M |
| Operating Cash Flow | (67.75M) | (105.45M) | (97.38M) | (119.19M) | (157.24M) |
| Capital Expenditures | (334K) | (596K) | (66K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2K | 0 | 0 |
| Investing Cash Flow | (334K) | (596K) | (64K) | 0 | 0 |
| Debt Repayment | 0 | 0 | 29.59M | 0 | 0 |
| Common Stock Issued | 154.79M | 440K | 144.94M | 26.22M | 141.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 600K | (690K) | 37.61M | (328.83K) |
| Financing Cash Flow | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Effect of Forex Changes | (5.58M) | (24.96M) | 867K | 194K | 1.05M |
| Net Change in Cash | 82.99M | (129.97M) | 77.26M | (55.17M) | (15.48M) |
| Free Cash Flow | (68.08M) | (106.05M) | (97.44M) | (119.19M) | (157.24M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.